ReNeuron Group plc Director Change (3606B)
11 Février 2022 - 8:00AM
UK Regulatory
TIDMRENE
RNS Number : 3606B
ReNeuron Group plc
11 February 2022
ReNeuron Group plc
("ReNeuron" or the "Company")
Director Change
ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell
and Exosomes Technologies, announces that Olav Hellebø is standing
down as CEO and executive director of the Company and will leave
the Company on 28 February 2022.
With immediate effect Iain Ross, Chairman, supported by
Catherine Isted, CFO and the leadership team, will assume
responsibility for the running of the business as the Company
transitions to focus primarily on the development of its Exosome
Technology Platform.
Olav Hellebø, commented : "Following ReNeuron's recent change in
strategy, the time has come for me to pursue other opportunities. I
would like to thank employees and other stakeholders who have been
instrumental in pursuing our pioneering technologies over many
years."
Iain Ross, Chairman of ReNeuron, commented: " On behalf of the
Board and Management I would like to recognise Olav's contribution
to the Company over the last 7 years and wish him well in the
future."
Further announcements will be made in due course.
ENDS
Contacts:
ReNeuron www.reneuron.com/investors
Iain Ross, Chairman Via Walbrook PR
Catherine Isted, Chief Financial Officer
Stifel Nicolaus Europe Limited (NOMAD
and Joint Broker)
Ben Maddison, Stewart Wallace +44 (0)20 7710 7600
Allenby Capital Limited (Joint Broker) +44 (0)20 3328 5656
James Reeve/George Payne (Corporate
Finance)
Stefano Aquilino (Sales & Corporate
Broking)
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7407
Paul McManus/Alice Woodings 804 654
About ReNeuron
ReNeuron is a UK based Proprietary Stem Cell based Exosome
Technologies company, harnessing its unique stem cell technologies
to develop 'off the shelf' treatments for diseases with significant
unmet needs.
ReNeuron's stem cell derived proprietary Exosome Technology
platform offers a delivery mechanism for a variety of payloads such
as siRNA, mRNA, proteins, small molecules and genes. The Company
has a growing number of partner collaborations with Global Pharma,
Biotech and academic partners in this fast-expanding area of
scientific and commercial interest. ReNeuron also has the ability
through its conditionally immortalised induced pluripotent stem
cell (iPSC) platform to make allogeneic tissue cells of choice and
has the potential to produce exosomes with tissue specific
targeting ability.
The Company also has a Phase 2 cell therapy candidate in
retinitis pigmentosa which it plans to out-license and also has
out-licensed its CTX programme in stroke disability to Fosun in
China.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. For further information visit www.reneuron.com
This announcement contains inside information. The person
responsible for arranging for the release of this announcement on
behalf of the Company is Catherine Isted, Chief Financial
Officer.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOASFFFASEESEDE
(END) Dow Jones Newswires
February 11, 2022 02:00 ET (07:00 GMT)
Reneuron (LSE:RENE)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
Reneuron (LSE:RENE)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025
